Printer Friendly

FDA accepts Arrowheada[euro](tm)s IND for obesity drug candidate Adipotide.

M2 PHARMA-January 5, 2012-FDA accepts Arrowheada[euro](tm)s IND for obesity drug candidate Adipotide(C)2012 M2 COMMUNICATIONS

5 January 2012 - Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company engaged in development of therapeutic products for cancer and obesity, said on Wednesday that the US Food and Drug Administration (FDA) had accepted the company's Investigational New Drug Application (IND) for its obesity drug candidate Adipotide.

This means that Arrowhead now has the green light to begin a clinical trial to test the safety of the compound.

Adipotide is designed to target and kill blood vessels supplying white fat tissue. The Phase I clinical study will be conducted by The University of Texas MD Anderson Cancer Center, which will secure the funding needed for the planned clinical trial.

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 5, 2012
Previous Article:Basilea to seek European approval for antibiotic ceftobiprole in H2 2012.
Next Article:Alkermes unveils positive results of Phase I/II MDD trial of ALKS 5461.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters